RAPT Therapeutics, Inc. (RAPT) Cash & Current Investments (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Cash & Current Investments for 5 consecutive years, with $97.9 million as the latest value for Q3 2024.
- Quarterly Cash & Current Investments fell 47.01% to $97.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $97.9 million through Sep 2024, down 47.01% year-over-year, with the annual reading at $158.8 million for FY2023, 36.25% down from the prior year.
- Cash & Current Investments hit $97.9 million in Q3 2024 for RAPT Therapeutics, down from $114.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $249.1 million in Q4 2022 to a low of $97.9 million in Q3 2024.
- Historically, Cash & Current Investments has averaged $167.7 million across 5 years, with a median of $173.0 million in 2022.
- Biggest five-year swings in Cash & Current Investments: soared 75.81% in 2022 and later tumbled 47.01% in 2024.
- Year by year, Cash & Current Investments stood at $111.5 million in 2020, then skyrocketed by 70.08% to $189.7 million in 2021, then skyrocketed by 31.33% to $249.1 million in 2022, then tumbled by 36.25% to $158.8 million in 2023, then tumbled by 38.34% to $97.9 million in 2024.
- Business Quant data shows Cash & Current Investments for RAPT at $97.9 million in Q3 2024, $114.8 million in Q2 2024, and $141.6 million in Q1 2024.